Phosphorus-containing prodrugs

Details Phosphorus-containing prodrugs Phosphorus-containing prodrugs

2010-09-24

2011-12-20

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C558S081000

Reexamination Certificate

active

08080536

ABSTRACT:
Novel cyclic phosphoramidate prodrugs of drugs of formula Itheir use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.

REFERENCES:
patent: 3018302 (1962-01-01), Bielefeld et al.
patent: 3404178 (1968-10-01), Roy
patent: 3796700 (1974-03-01), Yoshioka et al.
patent: 4255566 (1981-03-01), Carrico et al.
patent: 4318982 (1982-03-01), Hornby et al.
patent: 4340668 (1982-07-01), Hornby et al.
patent: 4376165 (1983-03-01), Hornby et al.
patent: 4447529 (1984-05-01), Greenquist et al.
patent: 4621077 (1986-11-01), Rosini et al.
patent: 4659825 (1987-04-01), Holy et al.
patent: 4705651 (1987-11-01), Staibano
patent: 4724232 (1988-02-01), Rideout et al.
patent: 4724233 (1988-02-01), De Clercq et al.
patent: 4777163 (1988-10-01), Bosies et al.
patent: 4804655 (1989-02-01), Müller et al.
patent: 4808716 (1989-02-01), Holy et al.
patent: 4861759 (1989-08-01), Mitsuya et al.
patent: 4879277 (1989-11-01), Mitsuya et al.
patent: 4882142 (1989-11-01), Simon et al.
patent: 4898724 (1990-02-01), Simon et al.
patent: 4939130 (1990-07-01), Jaeggi et al.
patent: 4952575 (1990-08-01), Sauerbier et al.
patent: 4952740 (1990-08-01), Juge et al.
patent: 5034394 (1991-07-01), Daluge
patent: 5047533 (1991-09-01), Reist et al.
patent: 5089500 (1992-02-01), Daluge
patent: 5130303 (1992-07-01), Akiyama et al.
patent: 5153183 (1992-10-01), Kawabe et al.
patent: 5157027 (1992-10-01), Biller et al.
patent: 5204355 (1993-04-01), Zsadon et al.
patent: 5210085 (1993-05-01), Liotta et al.
patent: 5212304 (1993-05-01), Fung et al.
patent: 5240946 (1993-08-01), Kinney et al.
patent: 5246937 (1993-09-01), Hamden et al.
patent: 5258538 (1993-11-01), Fung et al.
patent: 5366965 (1994-11-01), Strein
patent: 5480875 (1996-01-01), Isomura et al.
patent: 5532225 (1996-07-01), Reist et al.
patent: 5583122 (1996-12-01), Benedict et al.
patent: 5658889 (1997-08-01), Gruber et al.
patent: 5663159 (1997-09-01), Starrett, Jr. et al.
patent: 5681590 (1997-10-01), Bechard et al.
patent: 5721219 (1998-02-01), Ingall et al.
patent: 5814639 (1998-09-01), Liotta et al.
patent: 5840716 (1998-11-01), Ubasawa et al.
patent: 5869467 (1999-02-01), Holy et al.
patent: 5914331 (1999-06-01), Liotta et al.
patent: 5962522 (1999-10-01), Wacher et al.
patent: 6004927 (1999-12-01), Benet et al.
patent: 6028054 (2000-02-01), Benet et al.
patent: 6054587 (2000-04-01), Reddy et al.
patent: 6110903 (2000-08-01), Kasibhatla et al.
patent: 6117873 (2000-09-01), Acklin et al.
patent: 6284748 (2001-09-01), Dang et al.
patent: 6294672 (2001-09-01), Reddy et al.
patent: 6312662 (2001-11-01), Erion et al.
patent: 6399782 (2002-06-01), Kasibhatla et al.
patent: 6489476 (2002-12-01), Dang et al.
patent: 6752981 (2004-06-01), Erion et al.
patent: 6756360 (2004-06-01), Erion et al.
patent: 6946115 (2005-09-01), Erion et al.
patent: 7205404 (2007-04-01), Erion et al.
patent: 7303739 (2007-12-01), Erion et al.
patent: 492 738 (1970-06-01), None
patent: 35 12 781 (1985-04-01), None
patent: 0 002 062 (1979-05-01), None
patent: 0 072 987 (1982-08-01), None
patent: 0 072 531 (1983-02-01), None
patent: 0 158 057 (1985-10-01), None
patent: 0 161 955 (1985-11-01), None
patent: 0 261 283 (1986-09-01), None
patent: 0 180 276 (1988-12-01), None
patent: 0 338 372 (1989-10-01), None
patent: 0 353 692 (1990-07-01), None
patent: 0 481 214 (1992-04-01), None
patent: 1 165 570 (2002-01-01), None
patent: 987378 (1970-09-01), None
patent: 62-195392 (1987-08-01), None
patent: 62/249996 (1987-10-01), None
patent: WO 90/08155 (1990-07-01), None
patent: WO 90/10636 (1990-09-01), None
patent: WO 91/19721 (1991-12-01), None
patent: 96/01267 (1996-01-01), None
patent: 97/03679 (1997-02-01), None
patent: WO 97/22614 (1997-06-01), None
patent: 98/09668 (1998-03-01), None
patent: 98/39342 (1998-09-01), None
patent: 98/39343 (1998-09-01), None
patent: 98/39344 (1998-09-01), None
patent: WO 99/45016 (1999-09-01), None
patent: WO 01/39724 (2001-06-01), None
Alarcon, “Studies on the In Vivo Formation of Acrolein: 3-Hydroxy-propylmercapturic Acid as an Index of Cyclophosphamide (NSC-26271) Activiation,”Cancer Treatment Reports60(4):327-335, U.S. National Cancer Institute (1976).
Alexander et al., “Preparation of 9-(2-Phosphonomethoxyethyl) Adenine Esters as Potential Prodrugs,”Collect. Czech. Chem. Chem. Commun.59:1853-1869, Nakladatelstvi Ceskoslovenski Akademie Ved. (1994).
Amin et al., “1-Hydroxy-3-(methylpentylamino)-propylidene-1, 1-bisphosphnic Acid as a Potent Inhibitor of Squalene Synthase,”Arzneim.-Forsch/Drug Res.46(8):759-762 Editio Cantor (1996).
Anderson et al., “Cyclophosphamide and 4-Hydroxycyclophosphamide/Aldophosphamide Kinetics in Patients Receiving High-Dose Cyclophosphamide Chemotherapy,”Clinical Cancer Research2:1481-1487 (1996).
Annaert et al., “Transport, Uptake, and Metabolism of the Bis(pivaloyloxymethyl)-Ester Prodrug of 9-(2-Phosphonylmethoxyethyl) Adenine in an In Vitro Cell Culture System of the Intestinal Mucosa (Caco-2),”Pharm. Res.14(4):492-496 (1997).
Arnér et al., Mammalian Deoxyribonculeoside Kinases,Pharmac. Ther.67(2):155-186 (1995).
Arnold et al., “Über Beziehungen zwischen chemischer Konstitution and cancerotoxischer Wirkung in der Reihe der Phosphamidester des Bis-(β-chloräthyl)-amins,”Arzeimittel Forschung. Drug Research11:143-158, ECV Editio Cantor Verlag, Aulendorf, Germany (1961).
Atiq et al., “Treatment of Unresectable Primary Liver Cancer with Introhepatic Fluorodeoxyuridine and Mitomycin C Through an Implantable Pump,”Cancer69(4):920-924 (1992).
Auberson et al., “N-Phosphonoalkyl-5-Aminomethylquinoxaline-2, 3-Diones: In Vivo Active AMPA and NMDA-(Glycine) Antagonists,”Bioorg. Med. Chem. Lett.9:249-254 (1999).
Baker et al., “Microtiter Plate Assay for the Measurement of Glutathione and Glutathione Disulfide in Large Numbers of Biological Samples,”Annal. Biochem.190:360-365 (1990).
Balthazor et al., “Nickel-Catalyzed Arbuzov Reaction: Mechanistic Observations,”J. Org. Chem.45:5425-5426 (1980).
Banker et al., “Modern Pharmaceutics, 3ed.,” Marcel Dekker, New York, 1996, pp. 451 and 596.
Beaucage et al., The Synthesis of Modified Oligonucleotides by the Phosphoramidite Approach and Their Applications,Tetrahedron49(28):6123-6194 (1993).
Bedford et al., “Synthesis of Water-Soluble Prodrugs of the Cytotoxic Agent Combretastatin A4,”Bioorg. Med. Chem. Lett.6(2):157-160 (1996).
Beilstein Registry No. 3635189,Beilstein Institut zur Foerderung der Chemischen Wissenschatten(1991).
Bentrude et al..Am. Chem. Soc.,108(21):6669-6675 (1986).
Bentrude et al.,J. Am. Chem. Soc.,110(20:7119-7127 (1988).
Bentrude et al., “Stereo- and Reglochemistries of the Oxidations of 2-Methoxy- 5-tert-butyl-1,3,2-dioxaphosphorinanes and the Cyclic Methyl 3′5′-Phosphite of Thymidine by H2O/12and O2/AIBN to P-Chiral Phosphates.17O NMR Assignment of Phosphorus Configuration to the Diasteromeric Thymidine Cyclic Methyl 3′5′-Monophosphates,”J. Am. Chem. Soc.111:3981-3987 (1989).
Berry et al., “High-Yield Preparation of Isolated Rat Liver Parenchymal Cells,”J. of Cell Biology43:506-520 (1969).
Bespalov et al., “Prolongation of Morphine Analgesia by Competitive NMDA Receptor Antagonist D-CPPene (SDZ EAA 494) in Rats,”Eur. J. Pharmacol.351:299-305 (1998).
Bijsterbosch et al., “Disposition of the Acyclic Nucleoside Phsophonate (S)-9-(3-Hydroxy-2-Phosphonylmethoxypropyl) Adenine,”Antimicrobial Agents and Chemotherapy,42:1146-1150(1998).
Bijsterbosch et al., “Disposition of the Acyclic Nucleoside Phosphonate (S)9- (3-Hydroxy-2-Phosphonylmethoxyproply)Adenine,”Antimicrobial Agents and Chemotherapy42:1146-1150 (1998).
Bird et al., “Synthesis of NovelN-Phosphonoalkyl Dipeptide Inhibitors of Human Collagenase,”J. Med. Chem.37:158-169 (1994).
Boddy et al., “Individual Variation in the Activation and Inactivation of

Affiliated with

Also associated with

Rating

Phosphorus-containing prodrugs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phosphorus-containing prodrugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphorus-containing prodrugs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4253534